SEC Filing Summary: AntriaBio, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AntriaBio, Inc. on December 15, 2016. The filing serves as a Regulation FD disclosure, referencing a press release issued on the same date (Exhibit 99.1). The registrant is incorporated in Delaware with principal executive offices in Louisville, Colorado.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural disclosure of a press release rather than a financial statement.
Material Changes
The document does not detail specific material changes to financial performance or operations. It solely notifies the market of the issuance of a press release under Item 7.01.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, and specific risk factors are contained within the attached press release (Exhibit 99.1), which is not included in the provided text. The filing explicitly states that the information is "furnished" and not "filed" for purposes of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Verify the content of the press release dated December 15, 2016, referenced as Exhibit 99.1, as the 8-K text itself contains no operational details.
- Note that the registrant name in the filing is AntriaBio, Inc., despite the request metadata referencing "Rezolute, Inc."
- Confirm that the disclosure is furnished under Regulation FD and does not constitute a formal filing of financial data.